Expeditors International of Wshngtn Inc vs Medtronic PLC — how do they compare? Expeditors International of Wshngtn Inc trades at $181.17 (market cap $23.24B), while Medtronic PLC trades at $83.59 (market cap $103.01B). The key difference: Medtronic PLC is far larger — about 4.4× Expeditors International of Wshngtn Inc's market cap, and Medtronic PLC pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| EXPD | MDT | |
|---|---|---|
Market Cap | $23.24B | $103.01B |
Sector | Industrials | Health |
52-Week High | $178.22 | $105.35 |
52-Week Low | $111.37 | $73.75 |
Enterprise Value | $22.49B | $121.75B |
Dividend Yield | 0.91% | 3.58% |
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $180.87, up 1.49% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, posting Q1 2026 EPS of $1.71 versus $1.33 expected. Revenue grew to $11.07B in 2025 with a 7.48% net margin and impressive 36.59% ROE. Recent dividend of $0.81 reinforces shareholder returns while cash flow trends show operational strength.
Despite trading above the $161.50 consensus target, EXPD's earnings momentum and operational efficiency support continued upside potential. Key risks include analyst skepticism with only 12% buy ratings and overbought technical conditions. The stock's premium valuation requires sustained execution amid transportation industry challenges and economic uncertainties.
Medtronic (MDT) trades at $83.19, up 4.91% over the past 24 hours, with a technical outlook that is bearish based on moving averages but supported by neutral oscillators. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.55 surpassing the $1.54 estimate. Revenue grew to $33.54 billion in 2025, and the company maintains strong profitability with a net income margin of 13.2%. Recent corporate actions include a $0.72 dividend payment scheduled for July 2026.
The outlook for MDT is positive, supported by robust fundamentals, a favorable analyst consensus with a $97.50 price target, and a dividend aristocrat status. Key risks include increasing debt levels and competitive pressures in the medical device sector. The stock presents a long-term opportunity for growth and income, though near-term technical weakness may persist.
Trailing returns across standard periods
Latest headlines on both assets
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →